Antibiotic collateral sensitivity is contingent on the repeatability of evolution

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Nichol, Daniel ^a,b,i   Rutter, Joseph ^c   Bryant, Christopher ^d   Hujer, Andrea M ^c,d   Lek, Sai ^e   Adams, Mark D ^e   Jeavons, Peter ^a   Anderson, Alexander R A ^b   Bonomo, Robert A ^c,d,f,g   Scott, Jacob G ^a,d,h  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JACKSON LABORATORY   (United States)

^f LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFOTAXIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; FOSFOMYCIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ESCHERICHIA COLI; EVOLUTION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; IN VITRO STUDY; INDEL MUTATION; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REPRODUCTIVE FITNESS; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; BIOLOGICAL MODEL; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MUTATION; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; CEFOTAXIME; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; EVOLUTION, MOLECULAR; GENE EXPRESSION PROFILING; GENETIC FITNESS; GENOME, BACTERIAL; GENOTYPE; MICROBIAL SENSITIVITY TESTS; MODELS, GENETIC; MODELS, THEORETICAL; MUTATION; WHOLE GENOME SEQUENCING;

EID: 85060175916     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-08098-6     Document Type: Article

References (48)

1. Scott, J. & Marusyk, A. Somatic clonal evolution: a selection-centric perspective. Biochim. Biophys. Acta Rev. Cancer 1867, 139–150 (2017)
2. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433 (2010)
3. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012)
4. Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350, 1023–1035 (2004)
5. Mallet, J. The evolution of insecticide resistance: have the insects won? Trends Ecol. Evol. 4, 336–340 (1989)
6. Phillips, P. C. Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems. Nat. Rev. Genet. 9, 855 (2008)
7. Weinreich, D. M., Delaney, N. F., DePristo, M. A. & Hartl, D. L. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312, 111–114 (2006)
8. Poelwijk, F. J., Kiviet, D. J., Weinreich, D. M. & Tans, S. J. Empirical fitness landscapes reveal accessible evolutionary paths. Nature 445, 383 (2007)
9. Tan, L., Serene, S., Chao, H. X. & Gore, J. Hidden randomness between fitness landscapes limits reverse evolution. Phys. Rev. Lett. 106, 198102 (2011)
10. Imamovic, L. & Sommer, M. O. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 5, 204ra132–204ra132 (2013)
11. Kim, S., Lieberman, T. D. & Kishony, R. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc. Natl Acad. Sci. USA 111, 14494–14499 (2014)
12. Nichol, D. et al. Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance. PLoS Comput. Biol. 11, e1004493 (2015)
13. Fuentes-Hernandez, A. et al. Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages. PLoS Biol. 13, e1002104 (2015)
14. Toprak, E. et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 44, 101 (2012)
15. Lázár, V. et al. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9, 700 (2013)
16. Munck, C., Gumpert, H. K., Wallin, A. I. N., Wang, H. H. & Sommer, M. O. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci. Transl. Med. 6, 262ra156–262ra156 (2014)
17. Suzuki, S., Horinouchi, T. & Furusawa, C. Prediction of antibiotic resistance by gene expression profiles. Nat. Commun. 5, 5792 (2014)
18. Rodriguez de Evgrafov, M., Gumpert, H., Munck, C., Thomsen, T. T. & Sommer, M. O. Collateral resistance and sensitivity modulate evolution of high-level resistance to drug combination treatment in staphylococcus aureus. Mol. Biol. Evol. 32, 1175–1185 (2015)
19. Zhao, B. et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 165, 234–246 (2016)
20. Dhawan, A. et al. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Sci. Rep. 7, 1232 (2017)
21. Yu, H. et al. Analysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240–2247 (2013)
22. Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42 (2015)
23. Jiao, Y. J., Baym, M., Veres, A. & Kishony, R. Population diversity jeopardizes the efficacy of antibiotic cycling. Preprint available at https://www.biorxiv.org/content/early/2016/10/20/082107 (2016)
24. Barbosa, C. et al. Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effects. Mol. Biol. Evol. 34, 2229–2244 (2017)
25. Oz, T. et al. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol. Biol. Evol. 31, 2387–2401 (2014)
26. Wright, S. The roles of mutation, inbreeding, crossbreeding and selection in evolution. In Proceedings of the Sixth International Congress on Genetics, vol. 1, 356–366 (1932)
27. De Visser, J. A. G. & Krug, J. Empirical fitness landscapes and the predictability of evolution. Nat. Rev. Genet. 15, 480 (2014)
28. Palmer, A. C. et al. Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes. Nat. Commun. 6, 7385 (2015)
29. Mira, P. M. et al. Rational design of antibiotic treatment plans: a treatment strategy for managing evolution and reversing resistance. PLoS One 10, e0122283 (2015)
30. Cai, S. J. & Inouye, M. EnvZ–OmpR interaction and osmoregulation in Escherichia coli. J. Biol. Chem. 277, 24155–24161 (2002)
31. Jaffe, A., Chabbert, Y. A. & Semonin, O. Role of porin proteins ompf and ompc in the permeation of beta-lactams. Antimicrob. Agents Chemother. 22, 942–948 (1982)
32. Liu, Y.-F. et al. Loss of outer membrane protein c in escherichia coli contributes both to antibiotic resistance and escaping antibody-dependent bactericidal activity. Infect. Immun. 80, 1815–1822 (2012)
33. Adler, M., Anjum, M., Andersson, D. I. & Sandegren, L. Combinations of mutations in envz, ftsi, mrda, acrb and acrr can cause high-level carbapenem resistance in escherichia coli. J. Antimicrob. Chemother. 71, 1188–1198 (2016)
34. Ferenci, T. Maintaining a healthy SPANC balance through regulatory and mutational adaptation. Mol. Microbiol. 57, 1–8 (2005)
35. Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894–4903 (2009)
36. Enriquez-Navas, P. M. et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8, 327ra24–327ra24 (2016)
37. Yoon, N., Vander Velde, R., Marusyk, A., Scott, G.S. Optimal therapy scheduling based on a pair of collaterally sensitive drugs. Bull. Math. Biol. 80, 1776-1809 (2018)
38. Nichol, D., Bonomo, R.A., Scott, J.G. It's too soon to pull the plug on antibiotic cycling. Lancet. Infect. Dis. 18, P493 (2018)
39. Toprak, E. et al. Building a morbidostat: an automated continuous-culture device for studying bacterial drug resistance under dynamically sustained drug inhibition. Nat. Protoc. 8, 555 (2013)
40. Forde, S. E. et al. Understanding the limits to generalizability of experimental evolutionary models. Nature 455, 220 (2008)
41. Hinkley, T. et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat. Genet. 43, 487 (2011)
42. Kouyos, R. D. et al. Exploring the complexity of the HIV-1 fitness landscape. PLoS Genet. 8, e1002551 (2012)
43. Rice, L. B. et al. High-level expression of chromosomally encoded SHV-1 β-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44, 362–367 (2000)
44. Clinical & Laboratory Standards Institute, P., Wayne. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. CLSI document M100-S22. (2012)
45. Zerbino, D. & Birney, E. Velvet: algorithms for de novo short read assembly using de bruijn graphs. Genome Res. 18, 821–829 (2008)
46. McKenna, A. et al. The genome analysis toolkit: a mapreduce framework for analyzing next-generation dna sequencing data. Genome Res. 20, 1297–1303 (2010)
47. Siguier, P., Pérochon, J., Lestrade, L., Mahillon, J. & Chandler, M. Isfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res. 34, D32–D36 (2006)
48. Adams, M. D., Bishop, B. & Wright, M. S. Quantitative assessment of insertion sequence impact on bacterial genome architecture. Microb. Genom. 2, e000062 (2016)